Results 91 to 100 of about 40,497 (266)

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

Addiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts, John Strang, Caroline Copeland   +2 more
wiley   +1 more source

Antitumoral effects of cannabis in Notch1‐mutated T‐cell acute lymphoblastic leukemia

Cancer Communications, 2023
Elazar Besser, Anat Gelfand, Gil Moshe Lewitus, Hila Novak‐Kotzer, Shiri Procaccia, Paula Berman, Igal Louria‐Hayon, Inbar Shreiber‐Livne, Yishai Ofran, David Meiri   +9 more
doaj   +1 more source

Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics

Frontiers in Molecular Neuroscience
The individual and global burden of migraine is of such significance that there are accelerated efforts to develop new therapies. New migraine therapeutics are needed to address the current deficiencies that exist in the efficacy and adherence rate of ...
Kofi Frimpong-Manson, Yuma T. Ortiz, Lance R. McMahon, Jenny L. Wilkerson   +3 more
doaj   +1 more source

Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

Addiction, EarlyView.
Abstract Background and aims Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands.
Johanna J. Nugteren‐van Lonkhuyzen, Irma S. van den Hengel‐Koot, Claudine C. Hunault, Dylan W. de Lange, Antoinette J. H. P. van Riel, Laura Hondebrink   +5 more
wiley   +1 more source

Cannabis-Containing Cream for CKD-Associated Pruritus: A Double-Blind, Placebo Controlled Trial

Kidney Medicine
Rationale & Objective: This study aims to compare the efficacy of a cannabis cream and a placebo in the treatment of chronic kidney disease (CKD)-associated pruritus. Study Design: A double-blind randomized controlled study.
Suthiya Anumas, Pranporn Kuropakornpong, Panlop Chakkavittumrong, Adis Tasanarong, Pattharawin Pattharanitima   +4 more
doaj   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

The endocannabinoid system as a therapeutic target in intestinal fibrosis

Frontiers in Pharmacology
Intestinal fibrosis is a common and serious complication of inflammatory bowel diseases, often leading to strictures that require endoscopic or surgical intervention.
Zofia Misztal, Alicja Kaśniewska-Kosińska, Maria Wołyniak, Ewa Małecka-Wojciesko, Adam Fabisiak   +4 more
doaj   +1 more source

From emergence to replacement: The evolution of 3‐methylmethcathinone (3‐MMC) and its substitutes in the Dutch drug market (2012–2024)

Addiction, EarlyView.
Abstract Background and aims The market for new psychoactive substances (NPS) is highly dynamic, with hundreds of substances emerging on the European drug market in the last decade. 3‐methylmethcathinone (3‐MMC), a synthetic cathinone and isomer of mephedrone (4‐MMC), gained popularity in the Netherlands due to its psychostimulant effects and initial ...
Nadia Robert Petronella Wilhelmina Hutten, Pieter Edmond Oomen, Frederiek Schutten, Margriet Walburga van Laar, Laura Alexandra Smit‐Rigter   +4 more
wiley   +1 more source

Weighted prevalence of biochemically verified substance use in healthy adolescents across the USA

Addiction, EarlyView.
Abstract Background and aims Adolescent substance use is a significant public health concern, though the scope of the problem is difficult to ascertain given reliance on self‐reported substance use information. Recent, large cohort studies in adolescents and young adults suggest underreporting of substance use.
Natasha E. Wade, Yajuan Si, Susan F. Tapert, Janosch Linkersdörfer, Krista M. Lisdahl, Hailley R. Moore, Laila Tally, Biplabendu Das, Marilyn A. Huestis, Alexander L. Wallace, Ryan M. Sullivan, Veronica Szpak, Le Zhang, Laura Ziemer, Wesley K. Thompson   +14 more
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source